0001562180-24-001227.txt : 20240209
0001562180-24-001227.hdr.sgml : 20240209
20240209174327
ACCESSION NUMBER: 0001562180-24-001227
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240207
FILED AS OF DATE: 20240209
DATE AS OF CHANGE: 20240209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MOORE JOHN R
CENTRAL INDEX KEY: 0001191702
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40236
FILM NUMBER: 24616410
MAIL ADDRESS:
STREET 1: 3200 WALNUT ST
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc.
CENTRAL INDEX KEY: 0001710072
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 821725586
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1715 38TH ST
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: 720-262-7002
MAIL ADDRESS:
STREET 1: 1715 38TH ST
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-02-07
false
0001710072
Edgewise Therapeutics, Inc.
EWTX
0001191702
MOORE JOHN R
C/O EDGEWISE THERAPEUTICS, INC.
1715 38TH STREET
BOULDER
CO
80301
false
true
false
false
General Counsel
true
Common Stock
2024-02-07
4
M
false
17993.00
1.93
A
17993.00
D
Common Stock
2024-02-07
4
S
false
17993.00
20.0002
D
0.00
D
Common Stock
2024-02-08
4
M
false
3813.00
1.93
A
3813.00
D
Common Stock
2024-02-08
4
S
false
3813.00
20.0065
D
0.00
D
Common Stock
2024-02-09
4
M
false
8029.00
1.93
A
8029.00
D
Common Stock
2024-02-09
4
S
false
8029.00
20.0096
D
0.00
D
Stock Option (Right to Buy)
1.93
2024-02-07
4
M
false
17993.00
0.00
D
2030-12-15
Common Stock
17993.00
105004.00
D
Stock Option (Right to Buy)
1.93
2024-02-08
4
M
false
3813.00
0.00
D
2030-12-15
Common Stock
3813.00
101191.00
D
Stock Option (Right to Buy)
1.93
2024-02-09
4
M
false
8029.00
0.00
D
2030-12-15
Common Stock
8029.00
93162.00
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 30, 2023.
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.15, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date.
/s/ John R. Moore
2024-02-09